Clinical Trial Update: A Real-world Long-term Safety and Immunogenicity Study of Olipudase Alfa Therapy in Pediatric Patients Less Than 2 Years of Age With Acid Sphingomyelinase Deficiency (ASMD)

View source ↗

Summary

This is an ongoing real-world, long-term safety and immunogenicity study of olipudase alfa in infants under 2 years with acid sphingomyelinase deficiency (ASMD)…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acid Sphingomyelinase Deficiency
• Niemann-pick Disease Type

Drugs mentioned

• Olipudase alfa (olipudase alfa)

Snippet

Sponsor: Sanofi | Conditions: Niemann-Pick Diseases, Acid Sphingomyelinase Deficiency | Status: RECRUITING